Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review
There is evidence demonstrating that heart failure (HF) occurs in 1–2% of the global population and is often accompanied by comorbidities which contribute to increasing the prevalence of the disease, the rate of hospitalization and the mortality. Although recent advances in both pharmacological and...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/13/1/257 |
| _version_ | 1797410491016937472 |
|---|---|
| author | Vincenzo Mollace Giuseppe M. C. Rosano Stefan D. Anker Andrew J. S. Coats Petar Seferovic Rocco Mollace Annamaria Tavernese Micaela Gliozzi Vincenzo Musolino Cristina Carresi Jessica Maiuolo Roberta Macrì Francesca Bosco Marcello Chiocchi Francesco Romeo Marco Metra Maurizio Volterrani |
| author_facet | Vincenzo Mollace Giuseppe M. C. Rosano Stefan D. Anker Andrew J. S. Coats Petar Seferovic Rocco Mollace Annamaria Tavernese Micaela Gliozzi Vincenzo Musolino Cristina Carresi Jessica Maiuolo Roberta Macrì Francesca Bosco Marcello Chiocchi Francesco Romeo Marco Metra Maurizio Volterrani |
| author_sort | Vincenzo Mollace |
| collection | DOAJ |
| description | There is evidence demonstrating that heart failure (HF) occurs in 1–2% of the global population and is often accompanied by comorbidities which contribute to increasing the prevalence of the disease, the rate of hospitalization and the mortality. Although recent advances in both pharmacological and non-pharmacological approaches have led to a significant improvement in clinical outcomes in patients affected by HF, residual unmet needs remain, mostly related to the occurrence of poorly defined strategies in the early stages of myocardial dysfunction. Nutritional support in patients developing HF and nutraceutical supplementation have recently been shown to possibly contribute to protection of the failing myocardium, although their place in the treatment of HF requires further assessment, in order to find better therapeutic solutions. In this context, the Optimal Nutraceutical Supplementation in Heart Failure (ONUS-HF) working group aimed to assess the optimal nutraceutical approach to HF in the early phases of the disease, in order to counteract selected pathways that are imbalanced in the failing myocardium. In particular, we reviewed several of the most relevant pathophysiological and molecular changes occurring during the early stages of myocardial dysfunction. These include mitochondrial and sarcoplasmic reticulum stress, insufficient nitric oxide (NO) release, impaired cardiac stem cell mobilization and an imbalanced regulation of metalloproteinases. Moreover, we reviewed the potential of the nutraceutical supplementation of several natural products, such as coenzyme Q10 (CoQ10), a grape seed extract, <i>Olea Europea</i> L.-related antioxidants, a sodium–glucose cotransporter (SGLT2) inhibitor-rich apple extract and a bergamot polyphenolic fraction, in addition to their support in cardiomyocyte protection, in HF. Such an approach should contribute to optimising the use of nutraceuticals in HF, and the effect needs to be confirmed by means of more targeted clinical trials exploring the efficacy and safety of these compounds. |
| first_indexed | 2024-03-09T04:30:50Z |
| format | Article |
| id | doaj.art-67000e3caec5469099f0f4827156b4a3 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-09T04:30:50Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-67000e3caec5469099f0f4827156b4a32023-12-03T13:35:35ZengMDPI AGNutrients2072-66432021-01-0113125710.3390/nu13010257Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive ReviewVincenzo Mollace0Giuseppe M. C. Rosano1Stefan D. Anker2Andrew J. S. Coats3Petar Seferovic4Rocco Mollace5Annamaria Tavernese6Micaela Gliozzi7Vincenzo Musolino8Cristina Carresi9Jessica Maiuolo10Roberta Macrì11Francesca Bosco12Marcello Chiocchi13Francesco Romeo14Marco Metra15Maurizio Volterrani16Department of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyCardiology Clinical Academic Group, St George’s Hospitals NHS Trust University of London, London SW17 0QT, UKDepartment of Cardiology, Charité–Universitätsmedizin Berlin, 10117 Berlin, GermanyDepartment of Cardiology, IRCCS San Raffaele Pisana, 00166 Rome, ItalyFaculty of Medicine, Belgrade University, 11000 Belgrade, SerbiaDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, Institute of Research for Food Safety & Health, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalyDepartment of Diagnostic Imaging and Interventional Radiology, Policlinico Tor Vergata, 00199 Rome, ItalyDepartment of Experimental Medicine, University of Rome “Tor Vergata”, 00199 Rome, ItalyDepartment of Experimental and Applied Medicine, Institute of Cardiology, University of Brescia, 25121 Brescia, ItalyDepartment of Cardiology, IRCCS San Raffaele Pisana, 00166 Rome, ItalyThere is evidence demonstrating that heart failure (HF) occurs in 1–2% of the global population and is often accompanied by comorbidities which contribute to increasing the prevalence of the disease, the rate of hospitalization and the mortality. Although recent advances in both pharmacological and non-pharmacological approaches have led to a significant improvement in clinical outcomes in patients affected by HF, residual unmet needs remain, mostly related to the occurrence of poorly defined strategies in the early stages of myocardial dysfunction. Nutritional support in patients developing HF and nutraceutical supplementation have recently been shown to possibly contribute to protection of the failing myocardium, although their place in the treatment of HF requires further assessment, in order to find better therapeutic solutions. In this context, the Optimal Nutraceutical Supplementation in Heart Failure (ONUS-HF) working group aimed to assess the optimal nutraceutical approach to HF in the early phases of the disease, in order to counteract selected pathways that are imbalanced in the failing myocardium. In particular, we reviewed several of the most relevant pathophysiological and molecular changes occurring during the early stages of myocardial dysfunction. These include mitochondrial and sarcoplasmic reticulum stress, insufficient nitric oxide (NO) release, impaired cardiac stem cell mobilization and an imbalanced regulation of metalloproteinases. Moreover, we reviewed the potential of the nutraceutical supplementation of several natural products, such as coenzyme Q10 (CoQ10), a grape seed extract, <i>Olea Europea</i> L.-related antioxidants, a sodium–glucose cotransporter (SGLT2) inhibitor-rich apple extract and a bergamot polyphenolic fraction, in addition to their support in cardiomyocyte protection, in HF. Such an approach should contribute to optimising the use of nutraceuticals in HF, and the effect needs to be confirmed by means of more targeted clinical trials exploring the efficacy and safety of these compounds.https://www.mdpi.com/2072-6643/13/1/257heart failuredysfunctional cardiomyocytespatho-physiological mechanismsoxidative stressnutraceuticals |
| spellingShingle | Vincenzo Mollace Giuseppe M. C. Rosano Stefan D. Anker Andrew J. S. Coats Petar Seferovic Rocco Mollace Annamaria Tavernese Micaela Gliozzi Vincenzo Musolino Cristina Carresi Jessica Maiuolo Roberta Macrì Francesca Bosco Marcello Chiocchi Francesco Romeo Marco Metra Maurizio Volterrani Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review Nutrients heart failure dysfunctional cardiomyocytes patho-physiological mechanisms oxidative stress nutraceuticals |
| title | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review |
| title_full | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review |
| title_fullStr | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review |
| title_full_unstemmed | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review |
| title_short | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review |
| title_sort | pathophysiological basis for nutraceutical supplementation in heart failure a comprehensive review |
| topic | heart failure dysfunctional cardiomyocytes patho-physiological mechanisms oxidative stress nutraceuticals |
| url | https://www.mdpi.com/2072-6643/13/1/257 |
| work_keys_str_mv | AT vincenzomollace pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT giuseppemcrosano pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT stefandanker pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT andrewjscoats pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT petarseferovic pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT roccomollace pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT annamariatavernese pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT micaelagliozzi pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT vincenzomusolino pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT cristinacarresi pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT jessicamaiuolo pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT robertamacri pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT francescabosco pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT marcellochiocchi pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT francescoromeo pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT marcometra pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview AT mauriziovolterrani pathophysiologicalbasisfornutraceuticalsupplementationinheartfailureacomprehensivereview |